Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

ence of transmission of HBV, HCV, or HIV, and no clinically relevant anti-C1 inhibitor antibodies developed

In a poster entitled, 'Open-Label Use of Nanofiltered C1 Esterase Inhibitor (human) (nf-C1 INH) for the Prophylaxis of Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects,' Dr. Colin Broom M.D., ViroPharma Incorporated, Exton, PA, presented new open label results of Cinryze in preventing HAE attacks in 23 pediatric patients with HAE.  Data from this study included the following:

  • Cinryze reduced the frequency of HAE attacks from a median of 3.0 attacks per month at baseline to 0.39 attacks per month during Cinryze prophylaxis
  • In children, prophylactic doses of 1000 U of Cinryze every 3 to 7 days resulted in increases in antigenic and functional C1-INH levels comparable to those seen in adults; increases in functional C1-INH activity were maintained over time
  • There were no severe hypersensitivity reactions related to Cinryze; no discontinuations from study due to adverse events; no detectable anti-C1 INH antibodies; and no evidence of transmission of HBV, HCV, or HIV;
  • Adverse events considered to be possibly, probably, or definitely related to Cinryze were headache, nausea, and infusion site erythema, none of which were considered severe.

In addition, the WAO has joined with The American College of Allergy, Asthma and Immunology (ACAAI) and the American Gastroenterological Association (AGA) Institute in an innovative  initiative called "HAE:  Learn About It, Talk About It."  The peer-driven campaign is designed to foster communication between physicians on the front lines of the diagnosis and management of HAE. The addition of WAO as a "Learn About It, Talk About It" partner expands the program to a global audience. The program will be highlighted in booth 13 at the WAO meeting.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/17/2014)... , Alemania, December 17, 2014 ... año anterior, con un alto nivel de gasto en ... año fiscal 2013/14 (finalizado el 30 de septiembre de ... ciento a 4.287 millones de euros (año anterior: 4.190 ... la moneda desfavorables. Las ganancias (EBIT) crecieron un 14 ...
(Date:12/17/2014)... 17, 2014 With advancements in neurological ... market is seeing new growth, according to Kalorama ... account for the majority of market volume, newer ... images, which are creating opportunities for more sophisticated applications. ... growing at a rate of 4%, with world ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
(Date:12/20/2014)... (PRWEB) December 20, 2014 Developers of ... release of a new plugin for Final Cut Pro ... , “TranSlice Volume 5 allows users to create hand ... it.” Said Christina Austin, CEO of Pixel Film Studios. ... of professionalism while maintaining an easy to use interface.” ...
(Date:12/20/2014)... December 20, 2014 Today, Balfleet.com, one ... a Christmas Sale, offering 50%-70% off on its ... season. , The mother of the bride dresses from ... company is 24/7 accessible and takes pride in providing ... , “We are offering great discounts on our mother ...
(Date:12/19/2014)... Sub Zero Ice Cream is partnering up with ... the 28th from 2pm-6pm at the Expo Center on the ... FL. , Inquiries regarding time slots and signing up, email ... donating process, Sub Zero Ice Cream & Yogurt will be ... , About Sub Zero Ice Cream & Yogurt , ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 SuperCloset ... 5x5 SuperClone Rooms. SuperCloset continues to offer indoor growers ... Pair one of the new SuperClone Rooms with the ... perpetual, and turnkey indoor hydroponic grow room setup. , ... the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... TX (PRWEB) December 20, 2014 The ... a new injectable filler from respected cosmetic brand Juvéderm. ... occur naturally with age. The Medspa at Hendrick is ... development in skin care technology to its clients. , ... gel to be FDA-approved to treat the mid-face and ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... Greater International Representation, WASHINGTON, Aug. 12 ... participation of 37 Supporting Partner,Organizations from around ... Zealand, Russia and the United Kingdom, as ... in the U.S. These Supporting Partner,Organizations have ...
... Investment Trust Inc.,(NYSE: CRE ) ("Care"), a real ... and commercial mortgage debt,today announced an agreement in principle ... terms:, -- Care will receive an option to ... mortgage assets on an individual basis at any time ...
... The development and repair of heart tissue and blood ... ribonucleic acid (RNA) that is found nowhere else in ... found. , Because of its specificity to the cardiovascular ... therapeutic treatment, the researchers said. , "Manipulating this microRNA ...
... N.J., Aug. 12 Barr Pharmaceuticals,Inc. (NYSE: ... Barr Laboratories subsidiary has,signed a Settlement Agreement ... resolve the patent litigation involving Boehringer Ingelheim,s,Mirapex(R) ... Settlement,Agreement and a Supply Agreement to resolve ...
... the release of Sfetyworks™, a web-based, semi-automated ... quickly spot and measure the strength of ... condition found within large electronic healthcare databases. ... plc (GSK) and ProSanos. Several years in ...
... Ind., Aug. 12 Hillenbrand, Inc.,(NYSE: HI ... consistent,with $165.6 million reported in the third quarter ... third-quarter earnings per share, operating,profit and cash flow ... for the quarter remained essentially flat, even as ...
Cached Medicine News:Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 2Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 3Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 4Health News:Care Investment Trust Inc. Announces an Agreement in Principle for CIT Healthcare to Purchase Mortgage Assets and Reduce Management Fee 2Health News:Tiny molecule helps control blood-vessel development, UT Southwestern researchers find 2Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 2Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 3Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 4Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 5Health News: ProSanos Corporation Releases New Software System to Improve Patient Safety via Surveillance and Analysis of Claims and Electronic Health Records 2Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 2Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 3Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 4Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 5Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 6Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 7Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 8Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 9
... e-power series power supplies are ... gel electrophoresis system. These units ... the most rigorous safety standard, ... the most compact and powerful ...
... ZOOM® Dual Power is a microprocessor-controlled ... both high voltage/low current and high ... voltage/low current section is ideal for ... DNA sequencing applications. The low voltage/high ...
... These modified battery chargers ... supplies for GENIE blotters. ... produce very specific voltages, ... than laboratory power supplies. ...
... These modified battery ... power supplies for GENIE ... to produce very specific ... reproducibility than laboratory power ...
Medicine Products: